Cargando…
Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis
Antimitochondrial antibodies (AMA) are the serum hallmark of primary biliary cirrhosis (PBC). However, AMA-positivity can be found in non-PBC sera when lower dilutions are used, thus raising issues about the specificity and sensitivity of the test. AMA reacts primarily with the lipoylated domains of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270775/ https://www.ncbi.nlm.nih.gov/pubmed/17162370 http://dx.doi.org/10.1080/17402520600668706 |
_version_ | 1782151759828877312 |
---|---|
author | Miyakawa, Hiroshi Tanaka, Atsushi Selmi, Carlo Hosoya, Naomi Mataki, Norikazu Kikuchi, Kentaro Kato, Takashi Arai, Junya Goto, Toshihiro Gershwin, M. Eric |
author_facet | Miyakawa, Hiroshi Tanaka, Atsushi Selmi, Carlo Hosoya, Naomi Mataki, Norikazu Kikuchi, Kentaro Kato, Takashi Arai, Junya Goto, Toshihiro Gershwin, M. Eric |
author_sort | Miyakawa, Hiroshi |
collection | PubMed |
description | Antimitochondrial antibodies (AMA) are the serum hallmark of primary biliary cirrhosis (PBC). However, AMA-positivity can be found in non-PBC sera when lower dilutions are used, thus raising issues about the specificity and sensitivity of the test. AMA reacts primarily with the lipoylated domains of pyruvate dehydrogenase-E2 (PDC-E2) which is highly conserved across species, including bacteria. We studied 77 serum samples, including 24 from patients with anti-PDC-E2-positive PBC and 53 controls (16 with autoimmune hepatitis (AIH), 10 with primary sclerosing cholangitis (PSC), and 27 healthy individuals) for their reactivities at serial dilutions (1:10, 1:20 and 1:40) against Escherichia coli DH5 alpha lysate overexpressing human PDC-E2 using immunoblotting (IB). A murine anti-human PDC-E2 monoclonal antibody (mAB) was used as control. We further studied positive sera using adsorption with a synthetic E. coli peptide sharing similarity with human PDC-E2. Finally, we verified whether a unique buffer for E. coli preparation could reduce non-specific serum reactivity. Results demonstrated that 100% of anti-PDC-E2-positive PBC and up to 38% of control sera at 1:10 dilution recognized E. coli PDC-E2 at IB while dilution tests indicated that the overall potency of PBC reactivity was 100-fold higher compared to controls. In fact, a subgroup (20-38%) of non-PBC sera were positive at low titers but lost the reactivity when absorbed with the synthetic E. coli peptide. Finally, our unique buffer reduced the reactivity of non-PBC sera as measured by ELISA. In conclusion, we demonstrated that weak cross-reactivity with E. coli PDC-E2 occurs in non-PBC sera at lower dilutions and that such reactivity is not due to AMA-positivity. The use of a specific buffer might avoid the risk of false positive AMA determinations when E. coli-expressed recombinant antigens are used. |
format | Text |
id | pubmed-2270775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-22707752008-03-31 Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis Miyakawa, Hiroshi Tanaka, Atsushi Selmi, Carlo Hosoya, Naomi Mataki, Norikazu Kikuchi, Kentaro Kato, Takashi Arai, Junya Goto, Toshihiro Gershwin, M. Eric Clin Dev Immunol Research Article Antimitochondrial antibodies (AMA) are the serum hallmark of primary biliary cirrhosis (PBC). However, AMA-positivity can be found in non-PBC sera when lower dilutions are used, thus raising issues about the specificity and sensitivity of the test. AMA reacts primarily with the lipoylated domains of pyruvate dehydrogenase-E2 (PDC-E2) which is highly conserved across species, including bacteria. We studied 77 serum samples, including 24 from patients with anti-PDC-E2-positive PBC and 53 controls (16 with autoimmune hepatitis (AIH), 10 with primary sclerosing cholangitis (PSC), and 27 healthy individuals) for their reactivities at serial dilutions (1:10, 1:20 and 1:40) against Escherichia coli DH5 alpha lysate overexpressing human PDC-E2 using immunoblotting (IB). A murine anti-human PDC-E2 monoclonal antibody (mAB) was used as control. We further studied positive sera using adsorption with a synthetic E. coli peptide sharing similarity with human PDC-E2. Finally, we verified whether a unique buffer for E. coli preparation could reduce non-specific serum reactivity. Results demonstrated that 100% of anti-PDC-E2-positive PBC and up to 38% of control sera at 1:10 dilution recognized E. coli PDC-E2 at IB while dilution tests indicated that the overall potency of PBC reactivity was 100-fold higher compared to controls. In fact, a subgroup (20-38%) of non-PBC sera were positive at low titers but lost the reactivity when absorbed with the synthetic E. coli peptide. Finally, our unique buffer reduced the reactivity of non-PBC sera as measured by ELISA. In conclusion, we demonstrated that weak cross-reactivity with E. coli PDC-E2 occurs in non-PBC sera at lower dilutions and that such reactivity is not due to AMA-positivity. The use of a specific buffer might avoid the risk of false positive AMA determinations when E. coli-expressed recombinant antigens are used. Hindawi Publishing Corporation 2006 /pmc/articles/PMC2270775/ /pubmed/17162370 http://dx.doi.org/10.1080/17402520600668706 Text en Copyright © 2006 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Miyakawa, Hiroshi Tanaka, Atsushi Selmi, Carlo Hosoya, Naomi Mataki, Norikazu Kikuchi, Kentaro Kato, Takashi Arai, Junya Goto, Toshihiro Gershwin, M. Eric Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis |
title | Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis |
title_full | Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis |
title_fullStr | Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis |
title_full_unstemmed | Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis |
title_short | Serum Reactivity Against Bacterial Pyruvate Dehydrogenase: Increasing the Specificity of Anti-Mitochondrial Antibodies for the Diagnosis of Primary Biliary Cirrhosis |
title_sort | serum reactivity against bacterial pyruvate dehydrogenase: increasing the specificity of anti-mitochondrial antibodies for the diagnosis of primary biliary cirrhosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270775/ https://www.ncbi.nlm.nih.gov/pubmed/17162370 http://dx.doi.org/10.1080/17402520600668706 |
work_keys_str_mv | AT miyakawahiroshi serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis AT tanakaatsushi serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis AT selmicarlo serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis AT hosoyanaomi serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis AT matakinorikazu serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis AT kikuchikentaro serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis AT katotakashi serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis AT araijunya serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis AT gototoshihiro serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis AT gershwinmeric serumreactivityagainstbacterialpyruvatedehydrogenaseincreasingthespecificityofantimitochondrialantibodiesforthediagnosisofprimarybiliarycirrhosis |